이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tivic Health Systems 관리

관리 기준 확인 4/4

Tivic Health Systems' CEO는 Jennifer Ernst, Sep2016 에 임명되었습니다 의 임기는 7.75 년입니다. 총 연간 보상은 $ 329.34K, 83.5% 로 구성됩니다. 83.5% 급여 및 16.5% 보너스(회사 주식 및 옵션 포함). 는 $ 4.67K 가치에 해당하는 회사 주식의 0.19% 직접 소유합니다. 4.67K. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 4.5 년입니다.

주요 정보

Jennifer Ernst

최고 경영자

US$329.3k

총 보상

CEO 급여 비율	83.5%
CEO 임기	7.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	5.3yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Oct 17

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

CEO 보상 분석

Jennifer Ernst 의 보수는 Tivic Health Systems 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$329k	US$275k	-US$8m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$419k	US$275k	-US$10m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$249k	US$218k	-US$8m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$197k	US$181k	-US$4m
Dec 31 2019	US$226k	US$210k	-US$4m

보상 대 시장: Jennifer 의 총 보상 ($USD 329.34K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: Jennifer 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jennifer Ernst (56 yo)

7.8yrs

테뉴어

US$329,340

보상

Ms. Jennifer Ernst is a Co-Founder, CEO and Director of Tivic Health Systems, Inc. since September 2016 and was its Chief Financial Officer from September 2016 to July 2021. Ms. Ernst served as Chief Strat...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jennifer Ernst	Co-Founder	7.8yrs	US$329.34k	0.19% $ 4.7k
Blake Gurfein	Chief Scientific Officer	5.3yrs	US$405.02k	0.018% $ 436.7
Kimberly Bambach	Interim Chief Financial Officer	1.2yrs	데이터 없음	0.12% $ 2.9k

5.3yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: TIVC 의 관리팀은 노련하고 경험 (평균 재직 기간 5.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jennifer Ernst	Co-Founder	7.8yrs	US$329.34k	0.19% $ 4.7k
Sheryle Bolton	Independent Chair of the Board	5yrs	US$65.12k	0% $ 0
Howard Levine	Member of Medical Advisory Board	4.2yrs	데이터 없음	데이터 없음
Karen Drexler	Independent Director	5yrs	US$52.12k	0.0029% $ 70.7
Alan Goldsobel	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Dean Zikria	Independent Director	5yrs	US$37.12k	0% $ 0
Michael Foggs	Member of Medical Advisory Board	3.7yrs	데이터 없음	데이터 없음
Mitesh Popat	Member of Medical Advisory Board	3.5yrs	데이터 없음	데이터 없음
Annie Chern	Member of Medical Advisory Board?	2.5yrs	데이터 없음	데이터 없음

4.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: TIVC 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

Tivic Health Systems 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Recent updates

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

High number of new and inexperienced directors

No independent directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령